HIV SeropositivityHIV InfectionsHIV SeroprevalenceAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveAnti-Retroviral AgentsSubstance Abuse, IntravenousHIV-1Sexual BehaviorRisk FactorsDrug Resistance, ViralCD4 Lymphocyte CountViral LoadSeroepidemiologic StudiesReverse Transcriptase InhibitorsHIV Protease InhibitorsBenzoxazinesZidovudineDrug Resistance, Multiple, ViralAcquired Immunodeficiency SyndromeNevirapineHIVInfectious Disease Transmission, VerticalHIV Reverse TranscriptaseIndinavirRitonavirLopinavirPregnancy Complications, InfectiousStavudineOrganophosphonatesHIV ProteaseHIV Fusion InhibitorsRNA, ViralLamivudineNelfinavirDrug Therapy, CombinationPyrimidinonesSouth AfricaAdenineAIDS-Related Opportunistic InfectionsUgandaCohort StudiesMedication AdherenceIntegrase InhibitorsDidanosinePrevalenceHIV SeronegativityHIV-Associated Lipodystrophy SyndromeTreatment FailureSaquinavirZimbabweAntibodies, ViralViremiaHIV Integrase InhibitorsCross-Sectional StudiesPatient ComplianceAfrica South of the SaharaVirus ReplicationGenotypePregnancyTreatment OutcomeCD4-Positive T-LymphocytesDideoxynucleosidespol Gene Products, Human Immunodeficiency VirusAntibodies, BacterialHIV Wasting SyndromeMutationProspective StudiesChlamydophila pneumoniaeImmunoglobulin GDrug MonitoringMalawiChlamydophila InfectionsTime FactorsOxazinesSerologic TestsDrug InteractionsBrazilEnzyme-Linked Immunosorbent AssayCyclohexanesDeveloping CountriesRetrospective StudiesDrug Administration ScheduleGenes, polInfant, NewbornCommission on Professional and Hospital ActivitiesDrugs, GenericPyrrolidinonesAntiviral AgentsLipodystrophyIncidencePlasmaLongitudinal StudiesZalcitabineHIV Envelope Protein gp41Follow-Up StudiesProtease InhibitorsCoinfectionHelicobacter pyloriHelicobacter Infections